Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Nature Reviews. Clinical Oncology|July 25, 2012
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?Karin Beelen, Wilbert Zwart, Sabine C Linn
European Journal of Pharmacology|April 3, 2013
Tamoxifen resistance: from bench to bedsideMarjolein Droog, Karin Beelen, Sabine Linn, et al.
BMC Cancer|July 26, 2018
Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannotKarin Beelen, Mark Opdam, Tesa Severson, et al.
International Journal of Cancer|February 7, 2014
PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapyKarin Beelen, Laurien D C Hoefnagel, Mark Opdam, et al.
BMC Cancer|August 15, 2015
Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13Cristiane Bentin Toaldo, Xanthippi Alexi, Karin Beelen, et al.
Breast Cancer Research : BCR|January 29, 2014
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsKarin Beelen, Mark Opdam, Tesa M Severson, et al.
Breast Cancer Research : BCR|January 23, 2014
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatmentKarin Beelen, Mark Opdam, Tesa M Severson, et al.
Cancer Cell|October 16, 2007
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerKatrien Berns, Hugo M Horlings, Bryan T Hennessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA resultsRosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer PatientsRichard D Baird, Annelot G J van Rossum, Mafalda Oliveira, et al.
Pageof 2